Growth hormone-releasing factor releases ACTH from an AtT-20 mouse pituitary tumor cell line but not from normal pituitary cells

Life Sci. 1987 Jun 1;40(22):2161-7. doi: 10.1016/0024-3205(87)90006-3.

Abstract

Corticotropin-releasing factor (CRF) and both human pancreatic growth hormone-releasing factor (hp-GRF) and rat hypothalamic GRF (rh-GRF) stimulated ACTH release from neoplastic AtT-20 mouse pituitary tumor cells in a dose-dependent fashion, with CRF inducing a 10-fold increase and GRF a maximal increment of approximately one-half that of CRF. Neither rh-GRF nor hp-GRF induced ACTH release in normal anterior pituitary cells. Pretreatment with either dexamethasone or somatostatin prior to the addition of rh-GRF inhibited the increase in ACTH release. Both ovine CRF and rh-GRF stimulated adenosine 3,5-monophosphate production in AtT-20 cells. The weak but clearly discernible effect of GRF on ACTH release from AtT-20 cells may be due to an abnormality in the AtT-20 cell receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenocorticotropic Hormone / metabolism*
  • Animals
  • Cell Line
  • Cells, Cultured
  • Corticotropin-Releasing Hormone / pharmacology*
  • Cyclic AMP / metabolism
  • Dexamethasone / pharmacology
  • Growth Hormone-Releasing Hormone / pharmacology*
  • Mice
  • Pituitary Gland, Anterior / drug effects*
  • Pituitary Gland, Anterior / metabolism
  • Pituitary Neoplasms / metabolism*
  • Radioimmunoassay
  • Somatostatin / pharmacology

Substances

  • Somatostatin
  • Dexamethasone
  • Adrenocorticotropic Hormone
  • Corticotropin-Releasing Hormone
  • Growth Hormone-Releasing Hormone
  • Cyclic AMP